Ibnsina Pharma (EGX: ISPH)
Egypt
· Delayed Price · Currency is EGP 6.42
-0.09 (-1.38%)
At close: Dec 3, 2024
Ibnsina Pharma Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 48,546 | 33,949 | 22,264 | 21,733 | 18,679 | 16,600 | Upgrade
|
| Revenue Growth (YoY) | 60.44% | 52.48% | 2.45% | 16.35% | 12.52% | 24.59% | Upgrade
|
| Cost of Revenue | 44,881 | 31,434 | 20,648 | 20,103 | 17,212 | 15,161 | Upgrade
|
| Gross Profit | 3,664 | 2,515 | 1,617 | 1,630 | 1,467 | 1,439 | Upgrade
|
| Selling, General & Admin | 1,693 | 1,289 | 1,076 | 829.22 | 822.71 | 674.71 | Upgrade
|
| Other Operating Expenses | 3.71 | 5 | - | - | - | 10.67 | Upgrade
|
| Operating Expenses | 1,838 | 1,378 | 1,142 | 962.17 | 978.17 | 786.12 | Upgrade
|
| Operating Income | 1,827 | 1,137 | 475.22 | 667.35 | 488.69 | 653.33 | Upgrade
|
| Interest Expense | -1,513 | -1,044 | -477.09 | -284.18 | -255.32 | -252.51 | Upgrade
|
| Interest & Investment Income | 130.2 | 126.65 | 133.26 | - | - | - | Upgrade
|
| Earnings From Equity Investments | -1.42 | -1.13 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 58.71 | 38.53 | 38.41 | 0.28 | -0.3 | -1.57 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.63 | 10.37 | 4.76 | 86.01 | 56.73 | 20.57 | Upgrade
|
| EBT Excluding Unusual Items | 496.79 | 267.53 | 174.55 | 469.46 | 289.8 | 419.82 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.48 | 0.48 | 0.75 | 4.25 | 2.42 | 1.06 | Upgrade
|
| Legal Settlements | - | - | - | -48 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.37 | - | - | Upgrade
|
| Pretax Income | 497.27 | 268.02 | 175.31 | 425.34 | 292.22 | 420.88 | Upgrade
|
| Income Tax Expense | 51.13 | 54.74 | 4.43 | 110.95 | 67.56 | 92.11 | Upgrade
|
| Earnings From Continuing Operations | 446.14 | 213.27 | 170.87 | 314.4 | 224.66 | 328.77 | Upgrade
|
| Minority Interest in Earnings | -0 | 0.39 | 1.71 | 0.33 | - | - | Upgrade
|
| Net Income | 446.14 | 213.66 | 172.58 | 314.73 | 224.66 | 328.77 | Upgrade
|
| Preferred Dividends & Other Adjustments | 84.77 | 40.52 | 36.95 | 28.4 | 40.55 | 59.34 | Upgrade
|
| Net Income to Common | 361.37 | 173.14 | 135.63 | 286.33 | 184.11 | 269.43 | Upgrade
|
| Net Income Growth | 96.51% | 23.80% | -45.16% | 40.09% | -31.67% | 25.24% | Upgrade
|
| Shares Outstanding (Basic) | 1,008 | 1,008 | 1,008 | 1,302 | 1,120 | 1,120 | Upgrade
|
| Shares Outstanding (Diluted) | 1,008 | 1,008 | 1,008 | 1,302 | 1,120 | 1,120 | Upgrade
|
| Shares Change (YoY) | - | - | -22.58% | 16.25% | - | 1.54% | Upgrade
|
| EPS (Basic) | 0.36 | 0.17 | 0.13 | 0.22 | 0.16 | 0.24 | Upgrade
|
| EPS (Diluted) | 0.36 | 0.17 | 0.13 | 0.22 | 0.16 | 0.24 | Upgrade
|
| EPS Growth | 96.00% | 27.65% | -38.82% | 33.78% | -31.67% | 9.51% | Upgrade
|
| Free Cash Flow | 533.48 | -228.23 | -436.58 | -487.96 | 21.75 | -380.08 | Upgrade
|
| Free Cash Flow Per Share | 0.53 | -0.23 | -0.43 | -0.37 | 0.02 | -0.34 | Upgrade
|
| Dividend Per Share | - | - | - | 0.086 | - | - | Upgrade
|
| Gross Margin | 7.55% | 7.41% | 7.26% | 7.50% | 7.85% | 8.67% | Upgrade
|
| Operating Margin | 3.76% | 3.35% | 2.13% | 3.07% | 2.62% | 3.94% | Upgrade
|
| Profit Margin | 0.74% | 0.51% | 0.61% | 1.32% | 0.99% | 1.62% | Upgrade
|
| Free Cash Flow Margin | 1.10% | -0.67% | -1.96% | -2.25% | 0.12% | -2.29% | Upgrade
|
| EBITDA | 1,956 | 1,251 | 589.26 | 784.78 | 601.49 | 723.44 | Upgrade
|
| EBITDA Margin | 4.03% | 3.69% | 2.65% | 3.61% | 3.22% | 4.36% | Upgrade
|
| D&A For EBITDA | 129.84 | 114.18 | 114.04 | 117.43 | 112.8 | 70.11 | Upgrade
|
| EBIT | 1,827 | 1,137 | 475.22 | 667.35 | 488.69 | 653.33 | Upgrade
|
| EBIT Margin | 3.76% | 3.35% | 2.13% | 3.07% | 2.62% | 3.94% | Upgrade
|
| Effective Tax Rate | 10.28% | 20.43% | 2.53% | 26.08% | 23.12% | 21.89% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.